Physician profile
Ethan W Tolbert
NPI 1255537239
$54,493.99
in general payments reported to CMS, 2019-2025
30 companies · $8,629 in 2025
The $8,629 reported for 2025 was more than what 87% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $6,468 · 2021: $8,831 · 2022: $11K · 2023: $1,465 · 2024: $3,572 · 2025: $8,629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Food and Beverage: $1,611 · Education: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,902.50 |
| Food and Beverage | $1,611.48 |
| Education | $151.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $8,595.08 | 2019-2025 | Pomalyst, Opdivo |
| Pfizer INC. | $6,696.46 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $5,486.06 | 2022 | |
| Glaxosmithkline, LLC. | $4,861.02 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Genzyme Corporation | $4,294.78 | 2019-2025 | |
| Taiho Oncology, INC. | $4,132.50 | 2020-2021 | |
| Janssen Biotech, INC. | $4,103.29 | 2019-2025 | Talvey, Tecvayli, Rybrevant |
| Daiichi Sankyo INC. | $2,469.78 | 2022-2025 | Datroway, Vanflyta, Enhertu |
| Abbvie INC. | $2,325.44 | 2022-2025 | Venclexta |
| Incyte Corporation | $2,300.00 | 2021-2024 | Jakafi |
| Deciphera Pharmaceuticals INC. | $2,168.83 | 2021-2024 | Qinlock |
| Eisai INC. | $2,004.04 | 2019-2024 | |
| Karyopharm Therapeutics INC. | $1,550.00 | 2021 | |
| Seagen INC. | $1,272.73 | 2023 | Tukysa |
| Beigene USA, INC. | $697.03 | 2023-2024 | Brukinsa |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $552.25 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $404.15 | 2023-2025 | Enhertu, Imfinzi, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $94.76 | 2024-2025 | Ninlaro, Alunbrig |
| Genentech USA, INC. | $85.43 | 2024-2025 | Phesgo, Venclexta, Polivy |
| Gilead Sciences, INC. | $78.10 | 2021-2024 | |
| Tersera Therapeutics LLC | $68.77 | 2023-2025 | Xermelo |
| Novartis Pharmaceuticals Corporation | $51.05 | 2024 | |
| Merck Sharp & Dohme LLC | $48.85 | 2024-2025 | Keytruda |
| Regeneron Healthcare Solutions, INC. | $40.09 | 2024 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $30.37 | 2023-2025 | Opdualag |
| Servier Pharmaceuticals LLC | $19.31 | 2024 | |
| Sumitomo Pharma America, INC. | $18.55 | 2025 | Orgovyx |
| Array Biopharma INC | $18.31 | 2025 | Mektovi, Lorbrena, Braftovi |
| Helsinn Therapeutics (U.S.), INC. | $14.96 | 2021 | |
| Alexion Pharmaceuticals, INC. | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ethan Tolbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.